| 115.0628 0.033 (0.03%) | 04-27 11:33 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 134.47 | 1-year : | 157.06 |
| Resists | First : | 115.12 | Second : | 134.47 |
| Pivot price | 114.94 |
|||
| Supports | First : | 114.67 |
Second : | 114.38 |
| MAs | MA(5) : | 115.02 |
MA(20) : | 114.9 |
| MA(100) : | 88.77 |
MA(250) : | 79.46 |
|
| MACD | MACD : | 1.5  |
Signal : | 2.1 |
| %K %D | K(14,3) : | 79.4 |
D(3) : | 77.3 |
| RSI | RSI(14): 79.7 | |||
| 52-week | High : | 115.12 | Low : | 47.86 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ACLX ] has closed below upper band by 29.1%. Bollinger Bands are 97.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 30 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 115.21 - 115.87 | 115.87 - 116.47 |
| Low: | 113.47 - 114.2 | 114.2 - 114.87 |
| Close: | 113.98 - 115.16 | 115.16 - 116.21 |
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Mon, 27 Apr 2026
Are Medical Stocks Lagging Arcellx (ACLX) This Year? - Yahoo Finance
Fri, 24 Apr 2026
Arcellx (ACLX) details 2025 executive pay and board structure - Stock Titan
Tue, 21 Apr 2026
ACLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tue, 21 Apr 2026
Gilead (NASDAQ: ACLX) offers $115/share plus $5 CVR tied to $6B anito‑cel sales - Stock Titan
Fri, 17 Apr 2026
Gilead Sciences (NASDAQ: ACLX) offers $115 per share plus CVR; deadline extended - Stock Titan
Tue, 10 Mar 2026
Gilead to Acquire Arcellx, Inc. (ACLX) for Up to $7.8 billion - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 58 (M) |
| Held by Insiders | 4.225e+007 (%) |
| Held by Institutions | 12.8 (%) |
| Shares Short | 5,760 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.464e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 850.2 % |
| Return on Equity (ttm) | -24.1 % |
| Qtrly Rev. Growth | 2.229e+007 % |
| Gross Profit (p.s.) | -356.8 |
| Sales Per Share | -213.68 |
| EBITDA (p.s.) | -5.4128e+008 |
| Qtrly Earnings Growth | -4.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -210 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.54 |
| Price to Cash Flow | 4.13 |
| Dividend | 0 |
| Forward Dividend | 2.27e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|